Table 2

Clinical characteristics and their association with IL-6 and IL-8

		IL-6, n = 21		IL-8, n = 22

Characteristic	Median (IQR)	r	p value	r	p value
Olanzapine treatment
Years of treatment	4.5 (0.9–8.5)	−0.138	0.55	0.196	0.38
Daily dose, mg	10 (7.5–20)	0.074	0.75	−0.283	0.20
Hours from last dose to sampling	12 (10.25–12.75)	0.37	0.10	−0.064	0.78
Olanzapine, CSF, nM	10.9 (8.1–19.3)	−0.069	0.77	−0.078	0.73
Olanzapine, serum, nM	101 (71–171)	0.032	0.89	−0.139	0.54
Metabolic variables
BMI	26.2 (22.1–27.2)	0.025	0.92	−0.472	0.027
Plasma glucose, mg/dL	5.1 (4.9–5.4)	0.038	0.87	0.094	0.68
Plasma insulin, μIU/mL	45 (32–88)	−0.249	0.28	0.054	0.81
Plasma cholesterol, mg/dL	4.7 (4.4–5.5)	−0.065	0.78	0.043	0.85
Plasma triglycerides, mg/dL	1.3 (0.84–2.0)	−0.261	0.25	0.012	0.96
Other variables
Age, yr	35 (32–41)	0.062	0.79	0.002	0.99
GAF	58.0 (49–63)	0.15	0.52	0.235	0.29
BPRS	33.0 (27.0–35)	−0.122	0.60	−0.32	0.15
Age at first episode, yr	24 (20–28)	0.03	0.90	0.09	0.69
Duration of illness, yr	11 (5–15.25)	0.018	0.94	−0.04	0.86

BMI = body mass index; BPRS = Brief Psychiatric Rating Scale; CSF = cerebrospinal fluid; GAF = Global Assessment of Functioning scale; IL = interleukin; IQR = interquartile range.